A549 Cell Line human

86012804, human lung (carcinoma), Epithelial

• Synonyme(s) : A-549 Cells, A549 Cells, NCI-A549 Cells
• Code UNSPSC : 41106514

Propriétés

• product name: A549 Cell Line human, 86012804, from human lung(carcinoma)
• Source biologique: human lung (carcinoma)
• Mode de croissance: Adherent
• Caryotype: Hypotriploid
• Morphologie: Epithelial
• Produits: Lecithin, High amounts of de-saturated fatty acids.
• Récepteurs: Not specified
• Technique(s): cell culture | mammalian: suitable
• Maladie(s) pertinente(s): cancer
• Conditions d'expédition: dry ice
• Température de stockage: −196°C

Description

Origine de la lignée cellulaire

Human Caucasian lung carcinoma

Description de la lignée cellulaire

Derived from a 58 year old Caucasian male. The cells can synthesise lecithin utilising the cytidine diphosphocholine pathway. Occasional cells may also contain inclusion bodies although they are not known to carry any human pathogen.

Application

Enzymatic studies

Human A549 cell line has been used:

• to study the ability of 2-(2,4-dihydroxyphenyl)thieno-1,3-thiazin-4-one (BChTT) to inhibit cancer cell proliferation and identify mechanisms involved in its actions
• to study the effects of insulin and insulin-like growth factor 1 (IGF1) on proliferation and apoptosis in A549 cells
• to culture A549 cells in different media over a long term and identify conditions for promoting alveolar type II differentiation characteristics in A549 cells

Profil d'ADN

STR-PCR Data: Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 11
D16S539: 11,12
D5S818: 11
D7S820: 8,11
THO1: 8,9.3
TPOX: 8,11
vWA: 14

Milieu de culture

Ham′s F12K + 2mM Glutamine + 10% Foetal Bovine Serum FBS / FCS.

Procédure de repiquage

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10,000 cells/cm² using 0.25% Trypsin or tTrypsin/EDTA; 5% CO₂; 37°C.

Autres remarques

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.